BRIEF: MedBot reports strong year-to-date sales as commercialization accelerates

2252.HK
Jinxin does health AI

Shanghai MicroPort MedBot (Group) Co. Ltd. (2252.HK) said on Wednesday that cumulative orders for its core products, including laparoscopic, orthopedic, and vascular intervention surgical robots, surpassed 170 units as of this week.

Orders for its flagship product, the Toumai laparoscopic surgical robot, exceeded 100 units alone, with nearly 80 delivered worldwide, making it the dominant domestic player for such products. The company emphasized that its commercialization process has entered an accelerated phase.

Toumai is the first domestically developed laparoscopic robotic system to enter the global market. Overseas orders topped 60 units across 40 countries and regions spanning Asia, Europe, Africa, Oceania and South America, the company said.

Shares of MedBot opened down 1% at HK$32.86 on Thursday. The stock is up 250% since the beginning of the year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

, ,
, ,

Related Articles

RELATED ARTICLES

  1. Jinxin does health AI
    BRIEF: MicroPort ‘s revenue soars in first half of 2025
    2252.HK
  2. Feihe’s sliding profits point to China dairy market past its sell-by date
    6186.HK
  3. BRIEF: EHang reports wider loss, slashes 2025 revenue guidance
    EH.US
  4. BRIEF: Meitu reports strong profit growth in first half of 2025
    1357.HK
  5. China’s robotaxi commercialization faces hidden barriers
  6. Tuya accelerates AI strategy with 93% of shipped products featuring full AI integration
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Meta acquires Manus

Meta cuts Manus free from China, as regional lender gets premium bailout

In a landmark validation for Chinese AI, Facebook parent Meta has agreed to buy general AI agent maker Manus. But why is Meta also quite vehement about cutting all of Manus' China ties, both in terms of investors and business activity? And regional Chinese lender Weihai Bank has just received a major cash infusion from its local government in Shandong province. Is this a worrisome sign for investors?
META.US